Adjuvant Short-Course Trastuzumab in Breast Cancer
- 19 Downloads
The standard duration of adjuvant trastuzumab is 1 year. But the decision to use for 1 year was chosen arbitrarily in clinical trials. Many patients from developing countries like India cannot afford 1 year of adjuvant trastuzumab.
We retrospectively analysed 70 patients with HER2-positive breast cancer, who received short-course trastuzumab, and compared them with a matched historical cohort (n = 65) of HER2-positive breast cancer patients who did not receive trastuzumab.
The 1-year DFS and OS of patients who received short-course trastuzumab were 91% and 96%, respectively. This cohort was matched for age, stage and menopausal status with a historical cohort (N = 65) of HER2-positive breast cancer who did not receive trastuzumab. The 1-year DFS (94 vs 71%, p = 0.045) and 1-year OS (94 vs 80%, p = 0.006) were superior for those who received short-course trastuzumab.
Adjuvant short-course trastuzumab (weekly for 9 weeks) improved survival in HER2-positive breast cancer as compared to the historical cohort without trastuzumab.
KeywordsAdjuvant trastuzumab Short course Breast cancer
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Earl HM, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol. 2018;36:506–506.CrossRefGoogle Scholar
- 28.Gianni L, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.CrossRefGoogle Scholar